Qiming Venture Partners Portfolio Companies Shine on MIT Technology Review's 50 Smartest Companies List
The program seeks to identify smart companies that are changing the present and have the potential to shape the future.
Recently, the MIT Technology Review's annual 50 Smartest Companies (TR50) list was officially released. The selection aims to identify companies that are changing the present and have the potential to change the future.
Qiming Venture Partners portfolio companies Bilibili (NASDAQ:BILI, 09626.HK), StepFun, DeepWise, Infinigence AI, Xiaomi (01810.HK), Insilico Medicine, Insta360 (688775.SH), and Zhipu AI were selected.
Bilibili, StepFun, DeepWise
Infinigence AI, Xiaomi, Insilico Medicine
Insta360, Zhipu AI
Selected for
MIT Technology Review's 50 Smartest Companies list
· MIT Technology Review's 50 Smartest Companies list
According to the MIT Technology Review's definition, smart companies should possess two characteristics: intelligently developing and using new technologies, and intelligently understanding market and commercial opportunities. They blaze trails through technological innovation, combine sustainable business models, and extend technology's impact globally. Since establishing the "50 Smartest Companies" selection in 2010, the MIT Technology Review has been committed to uncovering innovation-driven enterprises with global influence. In 2019, the MIT Technology Review first introduced the concept of "China Pivot," bringing the "50 Smartest Companies" (TR50) selection to China. In each subsequent selection, the MIT Technology Review has proposed different core concepts based on technological developments and evolving trends, such as "China Focus" in 2020 and "China Leads" in 2021.
This year, guided by "Breaking Boundaries" and focused on "China's Future," the MIT Technology Review comprehensively analyzed multiple dimensions including technological innovation capability, globalization capacity, and commercialization ability to examine innovative forces that are "in China, by China, for China" — identifying through sustained technological, paradigmatic, and domain breakthroughs which enterprises will be capable of leading the next wave of technological development in China and worldwide.
In the current industrial transformation, smart technology companies are no longer pursuing single-point performance optimization, but rather systematic integration of emerging technologies through continuous technological innovation.**
Source | MIT Technology Review
Past Highlights
Qiming Stars | 2 Qiming Venture Partners Portfolio Companies Named to MIT Technology Review's 50 Smartest Companies List Qiming Honors | Qiming Venture Partners and Investors Named to 36Kr 2025 China Industrial Investors Annual List Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Selected for 2025 Shanghai Specialized and Innovative SMEs List and Innovative SMEs List (Second Batch)
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.